Oppenheimer lowered the firm’s price target on Keros Therapeutics (KROS) to $23 from $63 and keeps an Outperform rating on the shares after the company announced it voluntarily terminated Phase 2 TROPOS study of cibotercept/PAH following new observations of pericardial effusions. The company still plans to share full results from TROPOS in Q2 2025, informing the nature of PEs, treatment duration, exposure, and any benefit from cibotercept.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $32 from $33 at BofA
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz
- Morning Movers: Wells Fargo and Citi gain following Q4 earnings
- Keros Therapeutics voluntarily halts all dosing of Phase 2 TROPOS trial
- Keros Therapeutics Updates on Clinical Trials and Safety